Myelodysplastic syndromes: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• TP53 6
• IDH 12
• FLT3 6
• BCL-2 4
• CD19 5
• CD33 3
• RUNX1 0
• CD123 3
• JAK 3
• PARP 0
• TIM-3 0
• ABL1 0
• KMT2A 1
• CD47 0
• NPM1 2
• PD-1 1
• IL-1 2
• NLRP3 1
• ERK 0
• EZH2 0
• NRAS 0
• RAS 0
• SGLT2 1
• AKT 0
• CD20 1
• CD38 2
• CSF1R 2
• GLP-1 0
• IL-6 1
• PD-L1 0
• PI3K 1
• STING 1
• ALK 0
• AMPK 0
• AR 0
• ATM 0
• BCMA 1
• BRAF 0
• BRCA1 0
• BRCA2 0
• BTK 0
• CCR5 0
• CD22 1
• CD40 0
• COX-2 0
• CTNNB1 0
• GPRC5D 1
• GPX4 0
• HIF-1 0
• IL-15 1
• IL-17 0
• KIT 0
• KRAS 0
• MAPK 0
• MYC 0
• PRMT5 0
• RB1 0
• STAT3 0

5 of 5+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NCI · R44

  A Phase 2 Study of SX-682 in Combination with Nivolumab and Relatlimab in Melanoma Patients

  Syntrix Biosystems, Inc.· Auburn, United States· US$406,500 awarded in fiscal year 2026· until Aug 2027

• NIH NCI · DP2

  Single-molecule, Single-cell profiling of chromatin protein-protein interactions.

  Van Andel Research Institute· Grand Rapids, United States· US$912,000 awarded in fiscal year 2026· until Aug 2031

• NIH NIDDK · R01

  Role of IL-1 beta signaling in stress erythropoiesis

  Pennsylvania State University, the· University Park, United States· US$641,869 awarded in fiscal year 2026· until May 2030

• NIH NHLBI · R01

  Mechanisms underlying germline predisposition to clonal hematopoiesis

  Albert Einstein College of Medicine· Bronx, United States· US$693,151 awarded in fiscal year 2026· until May 2031

• NIH NHGRI · R01

  A single-cell multiomics platform for studying genome structure and function

  University of Washington· Seattle, United States· US$796,114 awarded in fiscal year 2026· until Aug 2030

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-SE

  Towards novel approaches for Myelodysplastic Syndromes diagnosis to Strengthen Research Human Capital with Cross-Sectoral and Interdisciplinary Staff mobility (DiagMDS)

  Idryma Iatroviologikon Ereunon Akademias Athinon· Athina, Greece· EU contribution €1,322,640· until Sept 2030· 9 countries

• European Commission (Horizon 2020) · ERC-COG

  Identifying spatial determinants of immune cell fate commitment (ImmuNiche)

  Julius-Maximilians-Universitat Wurzburg· Wuerzburg, Germany· EU contribution €1,997,500· until Dec 2026

7 of 170 running projects, newest first. Listed amounts together: US$121.5m + €3.3m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Efficacy and Safety of Canakinumab for the Treatment of Anemia in LR-MDS Patients

  NCT05237713· University of Leipzig· Updated 6 May 2024

  “Slow recruitment. It is not considered likely that the CANFIRE trial will be able to reach the target number of patients. Clinical responders will be further treated within the trial (expected duration: 3 years after stop of enrollment).”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 3
• CRISPR-Cas Systems 3
• Gene Expression Profiling 12
• Exome Sequencing 8
• Proteomics 2
• Metabolomics 1
• Mass Spectrometry 1
• Flow Cytometry 18
• Immunohistochemistry 1
• Liquid Biopsy 1
• Circulating Tumor DNA 1
• Xenograft Model Antitumor Assays 4
• Magnetic Resonance Imaging 8
• Machine Learning 8
• Deep Learning 3
• Cohort Studies 7

• A single-cell solution to a transplant mystery.

  Med, May 2026

• Imputing causality and clonal dynamics from single-cell transcriptomics in paroxysmal nocturnal hemoglobinuria.

  Leukemia, Apr 2026

• Prediction of myeloid malignant cells in Fanconi anemia using machine learning.

  PLoS One, Jan 2026

See which targets of this disease your abstract mentions, and go to the people working on them.